Stifel maintains Mettler-Toledo Intl at Buy, raises price target to $1900 from $1600

Stifel kept its Buy rating for Mettler-Toledo Intl and increased its price target to $1900 from $1600, suggesting a 10.3% upside from the Nov 6 close of $1722.15. The new target represents an 18.8% increase.

Original reporting
Published Nov 9, 2026, 12:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stifel maintains Mettler-Toledo Intl at Buy, raises price target to $1900 from $1600 — source image
Decision brief

The 30-second read

$MTDBullishMed
01

Why it matters

The higher target may attract short-term buyers and support the stock's price.

02

Market read

Analyst price target upgrades can move small- to mid-cap stocks, offering a modest trading edge.

03

What to watch

Potential supply-chain constraints and foreign exchange exposure.

Relevance 6/10Novelty 6/10Timing: post-market today

Background

Stifel's rating upgrade follows its routine coverage of Mettler-Toledo, a maker of weighing and precision instruments.

Company-level read

Ticker impact

$MTDBullishHigh confidence
Context

Stifel raised its price target for Mettler-Toledo Intl to $1900 from $1600, indicating a fresh bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

The new target implies a 10.3% upside from the recent close, prompting buying interest.

Market effects

May lift sentiment for industrial equipment and precision instruments sector.

US industrial stocks could see modest gains.

Limited to investors tracking precision instrument manufacturers.

Counterpoint

The target raise could be premature if macro demand weakens.

Key entities

  • Stifel

    Equity research firm issuing the rating upgrade.

  • Mettler-Toledo Intl

    Manufacturer of precision instruments.

Related articles

$MTDHighAI 8/10

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway?

Mettler-Toledo's stock rose 25% despite biotech funding freeze. Management's 2026 EPS guidance of $47.70-$47.90 exceeds consensus, with 2027 guidance also above expectations. Analysts' average price target is $1,590, but some, like Jefferies, raised targets to $1,930. The company expects $900M in free cash flow, supporting an $875M share buyback. Growth drivers include pharmacopeia revisions and GLP-1 manufacturing. Investors should evaluate service revenue and hardware cycles.

$MTDMed

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway? By Investing.com RSS CTA

Mettler-Toledo International (MTD) has risen 25.2% in two months, defying a biotech funding slowdown. The company, a key supplier of precision lab instruments, benefits from regulatory requirements in commercial drug production. Q3 results showed $1.09B revenue, $12.57 adjusted EPS, and strong margins. Management's 2026-2027 EPS guidance exceeds Wall Street estimates, with free cash flow supporting share buybacks.

$MTDMedAI 8/10

What Mettler-Toledo International (MTD) Said on Its Q3 Earnings Call

Mettler-Toledo (MTD) reported Q3 gross margin expansion to 59.8% and adjusted operating profit growth of 8%. The company raised its 2026 sales growth forecast to 5% and issued 2027 guidance, expecting 5% sales growth and adjusted EPS of $52.50-$53.50. Management highlighted opportunities in automation, digitalization, and U.S. onshoring, with potential upside from AI-driven instrument upgrades.

$MTDMed

Jefferies raises Mettler-Toledo stock price target on solid growth

Jefferies raised its price target for Mettler-Toledo (MTD) to $1,930, citing strong Q3 results with 6% local currency growth and improved 2026 outlook. The stock trades near its 52-week high, up 26.5% in six months. MTD reported Q3 adjusted earnings of $12.57 per share and revenue of $1.09 billion, both exceeding estimates. The company provided initial 2027 guidance with 5% growth and EPS of $52.50-$53.50, above consensus.